Loading organizations...
§ Private Profile · Geneva, Geneve, Switzerland
Medical device company developing image guidance systems for cardiac electrophysiology, focused on non-invasive proton beam therapy.
Based in Geneva, Switzerland, EBAMed is a medical device company developing an image guidance system that enables non-invasive proton beam therapy for the treatment of cardiac arrhythmias. The technology targets ventricular tachycardia by accounting for complex cardiac motion to deliver precise radiation-based ablation, addressing the complication rates of traditional catheter-based therapies. Originally founded in 1991 by Adriano Garonna, Giovanni Leo, Douglas Packer, and Ugo Amaldi, the enterprise currently operates under Chief Executive Officer Marina Izzo. To advance its technology vision, the venture-backed company has secured significant capital, including a EUR 14.35 million Series A round and an earlier CHF 1.2 million seed financing supported by Horizon 2020 grants. This financial backing comes from a prominent syndicate of institutional investors and strategic partners featuring Panakès Partners, the EIC Fund, OCCIDENT, and the Mayo Clinic.
EBAMed has raised $18.5M across 2 funding rounds.
EBAMed has raised $18.5M in total across 2 funding rounds.
EBAMed has raised $18.5M across 2 funding rounds. Most recently, it raised $15.7M Series A in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 28, 2023 | $15.7M Series A | EIC Fund, Barbara Castellano | EFI Lake Geneva Ventures, LIFTT, Mayo Clinic, Occident | Announced |
| Sep 23, 2020 | $2.8M Grant | European Innovation Council | — | Announced |
EBAMed has raised $18.5M in total across 2 funding rounds.
EBAMed's investors include EIC Fund, Barbara Castellano, EFI Lake Geneva Ventures, LIFTT, Mayo Clinic, OCCIDENT, European Innovation Council.